Press Releases

Compugen First Quarter 2011 Webcast and Conference Call Scheduled for Wednesday, May 11, 2011 at 10:00 AM EDT

May 3, 2011
Webcast to include updated company PowerPoint presentation

Tel Aviv, Israel, May 3, 2011 — Compugen Ltd. (NASDAQ: CGEN) today announced that the Company will host a live webcast and conference call at 10:00 AM EDT on Wednesday, May 11, 2011 to review first quarter 2011 results and to present an updated slide presentation of the company’s current status and outlook. The quarterly results will be released, and the slide presentation posted on the company’s website (, prior to the conference call.

To access the live webcast and presentation slides please go to Compugen’s website, located at audio portion will also be available via conference call, which can be accessed by dialing 1-888-407-2553 from the US, or +972-3-918-0610 internationally.

A replay of the conference call will be available approximately two hours after the completion of the live conference call. To access the replay, please dial 1-888-295-2634 from the US or +972-3-925-5928 internationally. The replay will be available through May 14, 2011.

About Compugen
Compugen is a leading drug and diagnostic discovery company providing novel product candidates addressing important unmet therapeutic and diagnostic needs to pharmaceutical, biotech and diagnostic companies under milestone and royalty bearing or other revenue sharing agreements. Unlike traditional high throughput trial and error experimental based discovery, Compugen’s discovery efforts consist of in silico (by computer) hypothesis-driven product candidate prediction and selection followed by in vitro and in vivo experimental validation. Compugen’ unique in silico prediction and selection capabilities are based on a broad and continuously growing infrastructure of proprietary scientific understandings and predictive platforms, algorithms, machine learning systems and other computational biology tools.Industry collaborations may be entered into before product candidate discovery is undertaken pursuant to “discovery on demand” type arrangements, or with respect to existing product candidates, can be initiated prior to, or at the proof of concept stage, or after selected preclinical activities have been undertaken by Compugen.In 2002, Compugen established an affiliate, Evogene Ltd. ( (TASE:EVGN.TA), to utilize certain of the Company’s in silico predictive discovery capabilities in agricultural biotechnology. For additional information, please visit Compugen’s corporate website at

This press release may contain “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995. These statements include words such as”may”, “expects”, “anticipates”, “believes”, and “intends”, and describe opinions about future events. These forward-looking statements involve known and unknown risks and uncertainties that may cause the actual results, performance or achievements of Compugen to be materially different from any future results, performance or achievements expressed or implied by such forward-looking statements. Some of these risks are: changes in relationships with collaborators; the impact of competitive products and technological changes; risks relating to the development of new products; and the ability to implement technological improvements. These and other factors are identified and more fully explained under the heading “Risk Factors” in Compugen’s annual reports filed with the Securities and Exchange Commission.

Company contact:
Marjie Hadad
Global Media Liaison
Compugen Ltd.
Tel: +972-54-536-5220